- The investment will double the facility's production capacity.
- Construction is scheduled to begin in 2022.
- Kromasil products are used in pharma, food, clinical, and environmental industries.
- Kromasil is vital for insulin purification and complex bio-pharma applications.
Expansion Plans
Nouryon plans to invest in its Kromasil manufacturing facility in Bohus, Sweden, to meet the increasing global demand from the pharmaceutical and biotechnology industries. The investment aims to double the facility’s existing production capacity, reinforcing Nouryon’s leadership in high-performance silica. Construction is scheduled to begin in 2022.
Industry Applications
Kromasil products are utilized by the pharmaceutical, food and beverage, clinical, and environmental industries. Applications range from laboratory analysis to industrial-scale purification. Notably, Kromasil plays a crucial role in the purification of insulin, contributing to improved diabetes treatment. Other uses include complex bio-pharma applications involving peptides, proteins, and hormones.
Market Demand
The bio-pharmaceutical market, particularly in India, China, and Southeast Asia, is experiencing significant growth. This facility expansion will enable Nouryon to meet the rising demand for Kromasil products in these regions, ensuring a steady supply of high-performance silica for the pharma and biotech industries.
